RxDoctor Payments Data

Christopher Walsh, MD

Urology · Wauwatosa, WINPI 1811966955

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $15,396 of the $20,595 with a category attached, or 74.8%. It is spread thinly across 44 manufacturers, the largest accounting for just 17.7%. Among urology clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$20,595in general payments, 2019–2025

Across 448 payments — averaging $45.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neotract Inc.$4K
  • Teleflex LLC$3K
  • Boston Scientific$2K
  • Medtronic$2K
  • Astellas Pharma US Inc$1K
  • Procept Biorobotics Corporation$1K
  • plus $7K from 38 others

What the payments were for

  • Speaking & faculty fees$3502%
  • Travel & lodging$4,49822%
  • Food & beverage$15,39675%
  • Education$3502%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,595 in reported general payments places this provider in the 95th percentile of 215 urology providers in Wisconsin.

See all urology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$185,920
Medicare patients
481
Services billed
2,636

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide46$659,810
GemtesaVibegron151$131,236
MyrbetriqMirabegron189$122,398
Tamsulosin Hcl713$6,542
Solifenacin Succinate111$4,454
Testosterone19$3,415
Potassium Citrate ErPotassium Citrate39$2,662
Ciprofloxacin Hcl337$1,662
Testosterone Cypionate34$1,557
Silodosin22$1,556
Estradiol11$1,424
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst64$1,213
Oxybutynin Chloride ErOxybutynin Chloride50$1,143
Bicalutamide38$1,133
Finasteride137$1,091

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$1,449$782,208235 claims
Sumitomo Pharma America, Inc.Gemtesa$181$131,236151 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 215 urology providers in Wisconsin.

Other urology in Wauwatosa

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →